Christopher L. Bowlus

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Michael Heneghan

Professor of Hepatology

King's College Hospital

UNITED KINGDOM

View details

James Park

Professor

University of Washington

UNITED STATES

View details

Charles McWherter

President and Chief Scientific Officer

UNITED STATES

View details

Aparna Goel

Assistant Clinical Professor

Stanford University School of Medicine

UNITED STATES

View details

Cynthia Levy

Professor of Medicine

University of Miami

UNITED STATES

View details

John Vierling

Professor of Medicine and Surgery (tenured); Chief of Hepatology

Baylor College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christopher L. Bowlus

Research Interests

Explore related searches

Contact this professor

Articles (21)

The effects of elafibranor in people with primary biliary cholangitis: a plain language summary

Primary biliary cholangitis: Personalizing second-line therapies

Pre‐Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis

Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy

Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results

Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC

Erratum: Primary biliary cholangitis: Personalizing second-line therapies

Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial

Development of the natural history component of an early economic model for primary sclerosing cholangitis.

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.

Editorial: The evolving paradigms and treatments for primary biliary cholangitis—Authors' reply

Correction to: Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Autoimmune Markers in Primary Biliary Cholangitis

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus

Recent Advances in the Management of Primary Sclerosing Cholangitis

Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC

Reply: Living donor liver transplantation for people with PSC

Automated electronic health registry‐based hepatitis B screening

Collaborators (6)

Michael Heneghan

James Park

Charles McWherter

Aparna Goel

Cynthia Levy

John Vierling

Make your next move.